BLBrian T. Lee

Brian T. Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian T. Lee has a total of 165 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The management of hepatorenal syndrome–acute kidney injury (HRS-AKI): A national survey of hepatology provider practices

    by Giuseppe Cullaro, Gene Y. Im, Shaun Chandna, Brian T. Lee, Douglas A. Simonetto, Elizabeth S. Aby, Manhal Izzy, Stevan A. Gonzalez, Courtney B. Sherman, Joshua Aron, et al.

    Background: Hepatorenal syndrome–acute kidney injury (HRS-AKI) is associated with high mortality in cirrhosis. Recent FDA approval of terlipressin and updated clinical guidance have expanded management options, but real-world practice patterns remain unknown. Methods: We conducted a nationwide survey of U.S. hepatology providers regarding HRS-AKI management practices. The 33-question survey assessed provider demographics, vasoconstrictor selection, treatment timing, and adherence to guideline recommendations. Results: Among 162 respondents, most were hepatologists (94%) at academic centers (83%). Only 11% obtained a nephrology consultation at AKI detection, with 44% waiting until worsening renal function. Terlipressin was available at 80% of institutions but more commonly at academic centers (84% vs. 53%, p =0.003). Consistent with guideline recommendations, 77% of providers initiate vasoconstrictors only after completing a trial of volume expansion (if no renal improvement), particularly in academic centers (80% vs. 60% non-academic, p =0.03). Terlipressin (49%) and midodrine/octreotide (44%) were preferred first-line treatments, with providers at academic centers more likely to use midodrine/octreotide (46% vs. 30%, p =0.008). Mean arterial pressure was used by 62% of providers to guide vasoconstrictor dosing. Most providers (73%) discontinued vasoconstrictor treatment after 4 days if no improvement. Conclusions: Significant variations exist between guideline recommendations and real-world HRS-AKI management, especially first-line treatment choice, treatment monitoring, and nephrology consultation. These findings highlight opportunities to improve guideline implementation and identify areas where practice patterns might inform provider education and future guidance updates.


  • Comparison of Kidney Allograft Outcomes in Simultaneous Liver‐Kidney Versus Kidney After Liver Transplantation Since the Safety Net Era

    by Brian T. Lee, Jennifer L. Dodge, Santhi Voora, Aaron Ahearn, Tse‐Ling Fong

    Background: Criteria for simultaneous liver kidney transplantation (SLKT) have undergone several iterations. In August 2017, the Organ Procurement Transplantation Network (OPTN) created specific criteria for SLKT allocation and established a “safety net” protocol to allocate kidney allografts for liver transplant recipients with persistent renal dysfunction within the first year after liver transplantation (KALT). Published studies that evaluated patient and kidney allograft survival have applied the “safety net” criteria retrospectively to time periods prior to enactment of the policy. We aimed to assess kidney allograft outcomes in those who underwent KALT compared to those who underwent SLKT during the actual “safety net” era. Methods: This retrospective cohort study included adults (≥18 years) receiving a primary kidney transplant via SLKT or safety net KALT from 2018 to 2021, captured in the OPTN database. Patients receiving multiple organs other than kidney‐liver, a kidney from a living donor, a split liver, or sequential or en bloc kidney transplant were excluded. Study outcomes, including kidney allograft survival, patient survival, eGFR and kidney rejection, were compared by KALT versus SLKT post‐kidney transplant. Differences in eGFR and rejection for KALT versus SLKT were then assessed in a propensity score analysis (nearest neighbor matching [ n = 4]) to estimate the conditional average treatment effect. Results: Between January 2018 and December 2021, 2620 patients underwent SLKT, and 526 underwent KALT by the safety net policy. Those who underwent KALT had a lower prevalence of diabetes mellitus (36.3% vs. 43.2%, p = 0.003). Alcohol as a reason for liver transplantation was higher in KALT versus SLKT (43.0 vs. 30.8%, p < 0.001). Recipients of KALT compared to SLKT had a higher prevalence of dialysis prior to transplant (73.2% vs. 53.5%, p < 0.001) with a higher median number of months of dialysis time (9.0 vs. 4.9 months, p < 0.001). At 1‐year post‐kidney transplant, KALT versus SLKT observed similar kidney allograft survival rates (97.7% [95%CI 96.0–98.7] vs. 96.8% [95%CI 96.0–97.4], p = 0.43) but higher patient survival rates (96.7% [95%CI 94.8–98.0] vs. 93.9% [95%CI 92.9–94.8] at 1 year [ p = 0.02]). Those with KALT consistently had lower eGFR at 6 months, 1 year, and 3 years after kidney transplantation. The mean difference at 1 year was −6.6 mL/min/1.73 m 2 (95% CI: −8.5 to −4.7, p < 0.001) in the unadjusted and −4.7 mL/min/1.73 m 2 (95% CI: −7.0 to −2.4, p < 0.001) in the propensity score matched analysis. At the longest follow‐up of 3 years, the mean difference remained −6.3 mL/min/1.73 m 2 (95%CI: −8.8 to −3.7, p < 0.001) in the unadjusted and −3.8 mL/min/1.73 m 2 (95% CI: −6.5 to −1.1, p = 0.005) in the propensity score matched analysis. While those with KALT had higher observed rates of rejection than SLKT throughout the period of 6 months, 1 year, and 3 years, propensity score matched analyses (adjusting for age, cPRA, HLA mismatch) did not show significant differences in rejection at all time points. Conclusion: While kidney allograft survival was similar, KALT recipients had significantly lower eGFR than their SLKT counterparts. Currently, there are inadequate data to determine if these findings can be attributed to differences in rejection rates, and longer‐term follow‐up of kidney allograft outcomes is needed.

  • Open Access

    Drug-Induced Liver Injury Secondary to Radionuclide Therapy With Lutetium-177 Vipivotide Tetraxetan in a Patient With Metastatic Castrate-Resistant Prostate Cancer

    by Brian T. Lee, Ravi J. Kankotia, David Braxton

    Lutetium-177 vipivotide tetraxetan (LuPSMA) is a small molecule inhibitor with high affinity to prostate-specific membrane antigen and is currently used in the treatment of metastatic castrate-resistant prostate cancer. Hepatotoxicity has seldom been reported. This is a case of drug-induced liver injury presenting in a patient who received 5 cycles of LuPSMA for metastatic castrate-resistant prostate cancer. In this report, we provide a probable case of drug-induced liver injury with imaging and histologic findings of cholestatic liver injury and stricturing cholangiopathy related to LuPSMA. This is the first report of LuPSMA as a probable cause of hepatotoxicity.

  • Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease

    by Richard Parker, Guru Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Brian T. Lee, Soyoun J. Park, Anne McCune, Timothy Morgan, et al.

    INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.


  • Open Access

    Differential Effects of Ascites and Hepatic Encephalopathy on Waitlist Mortality in Liver Transplantation by MELD 3.0

    by Brian T. Lee, Nathan T. Chen, Tse-Ling Fong, Jennifer L. Dodge

    Background. MELD 3.0 introduces changes to address waitlist disparities for liver transplant (LT) candidates. Ascites and hepatic encephalopathy (HE) are important milestones in the natural history of cirrhosis regardless of the Model for End-Stage Liver Disease (MELD) score. We aim to assess the impact of ascites and HE and its interaction with MELD 3.0 on waitlist mortality. Methods. This is a retrospective study of patients listed for LT in the Organ Procurement and Transplantation Network database from 2016 to 2021. The primary outcome was waitlist mortality (death/delisting for too sick to LT). Ascites/HE were classified as moderate ascites without moderate HE (mAscites), moderate HE without moderate ascites (mHE), both moderate ascites/HE (mBoth), and neither. MELD 3.0 scores were categorized as P < 0.001) for those with neither. In multivariable Cox regression, the adjusted risk of waitlist mortality associated with mAscites (versus neither) was a hazard ratio (HR) of 1.76 (95% confidence interval [CI], 1.55-2.00) when the MELD 3.0 score was P < 0.05 for all). A similar pattern was observed by MELD 3.0 for both moderate ascites/HE. Conclusions. The presence of moderate ascites alone, or combined with moderate HE, not only increases the risk of waitlist mortality but also has a differential effect by MELD 3.0, especially at lower MELD scores. Earlier strategies addressing this group and improving treatment plans or access to LT regardless of MELD remain needed.


  • Recurrent Liver Allograft Injury in Patients With Donor-Derived Malignancy Treated With Immunosuppression Cessation and Retransplantation

    by Brian T Lee, Naveen Ganjoo, M Isabel Fiel, Jackie F Hechtman, Suparna A Sarkar, Leona Kim-Schluger, Sander S Florman, Thomas D Schiano

    Objectives: Donor-derived malignancy of the liver allograft is a rare but serious condition in the setting of necessary immunosuppression. Retransplantation after abrupt immunosuppression cessation has been performed with durable cancer-free survival. Methods: We present 2 cases of patients with donor-derived malignancy who were treated with complete immunosuppression cessation, which induced rapidly progressive liver allograft rejection and failure, with a need for subsequent retransplantation. We reviewed all serial liver biopsies and explants from both patients and performed C4d immunostaining. Results: Initial explants of both patients showed severe allograft rejection, with unusual features of sinusoidal obstruction syndrome and C4d positivity. Malignant tumors in the explants were necrotic, related to rejection of donor-derived cancer cells and tissue. Follow-up of both patients has shown long-term cancer-free survival but issues with recurrent allograft failure requiring a third transplant. The reasons for retransplantation in both cases were related to allograft failure from antibody-mediated rejection. Conclusions: Clinicians should be aware of a potentially increased risk of rejection and recurrent allograft failure when strategizing treatment of donor-derived malignancy with immunosuppression cessation and retransplantation.


  • We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases

    by Brian T. Lee, Michele M. Tana, Jeffrey A. Kahn, Lily Dara

    Autoimmune liver diseases are attributed to a complex interplay of biologic, acquired, and environmental factors. Increased prevalence, later stage at presentation, worse response to standard therapy, and transplant‐related disparities have all been reported in racial and ethnic minorities such as Black and Latinx patients with autoimmune liver diseases. While biology and inherited genetic predispositions may partly explain these disparities, definitive and universal genetic variations underlying these differences in outcomes have not been defined. Nonetheless, socioeconomic status, access to health care, environmental and societal factors, and implicit provider bias can all contribute to poor patient outcomes. There remains an unmet need to understand and mitigate the factors contributing to health inequity in autoimmune liver diseases. In this review, we summarize the data on racial and ethnic disparities in presentation, treatment response, and outcomes pertaining to autoimmune liver diseases in minority populations, on the premise that understanding disparities is the first step toward reaching health equity.


  • Open Access

    Cholecystoduodenal fistula resulting in gallstone ileus: A path paved by stone

    by Brian T. Lee, Ahmad Mahamid, Jawad Ahmad, Parissa Tabrizian

    This report showcases the initial management of gallstone ileus which includes proper biliary assessment to assist with operative planning. While an uncommon condition, surgical management is crucial, although methodology may be variable.